2012
Immunotherapy for Cutaneous T-Cell Lymphoma
Modi B, Foss F, Edelson R, Girardi M. Immunotherapy for Cutaneous T-Cell Lymphoma. Contemporary Hematology 2012, 307-316. DOI: 10.1007/978-1-62703-170-7_18.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaToll-like receptor agonistsEffector T cell activityImmune effector mechanismsT cell activityGoal of therapyCytokine-based therapiesHistone deacetylase inhibitorsClinical responseMost patientsImmunotherapeutic approachesInterleukin-12Receptor agonistEffector mechanismsInterleukin-2Therapeutic approachesImmune functionDeacetylase inhibitorsTherapyCTCLPatientsLymphomaAttractive targetImmunotherapy
1995
Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes
Girardi M, Herreid P, Tigelaar R. Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes. Journal Of Investigative Dermatology 1995, 104: 177-182. PMID: 7829872, DOI: 10.1111/1523-1747.ep12612741.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAscitesAutoimmune DiseasesDisease Models, AnimalFemaleGlomerulonephritisGraft vs Host DiseaseGraft vs Host ReactionImmunotherapy, AdoptiveKidneyLupus Erythematosus, SystemicMiceMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAPUVA TherapyT-LymphocytesVaccinationConceptsSystemic lupus erythematosus-like diseaseB6D2F1 recipientsDisease initiationD2 cellsAntinuclear antibody titerLupus-like graftProgression of graftVersus Host DiseaseSystemic lupus erythematosusC3H/HeJ xDBA/2 splenocytesHost diseaseLupus erythematosusEffector lymphocytesClinical manifestationsClinical parametersHistologic evidenceAntibody titersKidney diseaseAscites formationB6D2F1 miceInterleukin-2T cellsC57BL/6 xComplex antigens